论文部分内容阅读
目的探讨新辅助化疗对Ⅲ期胃癌患者的疗效。方法胃恶性肿瘤患者130例,分为新辅助化疗组(NAC组)65例,常规化疗组(CC组)65例,比较两组患者区域淋巴结彻底清除率(R0切除率)、复发率及生存率。结果与CC组相比,NAC组的R0切除率高于CC组(P<0.05);NAC组的复发率术后12、24月低于CC组(P<0.05),NAC组的病死率术后6、12、24月低于CC组(P<0.05)。结论Ⅲ期胃癌新辅助化疗对提高患者R0切除率,降低胃癌术后复发率及病死率,效果优于传统的手术加术后化疗。
Objective To investigate the effect of neoadjuvant chemotherapy on patients with stage Ⅲ gastric cancer. Methods A total of 130 patients with gastric malignant tumor were divided into neoadjuvant chemotherapy group (NAC group) 65 cases and conventional chemotherapy group (CC group) 65 cases. The regional lymph node radical elimination rate (R0 resection rate), recurrence rate and survival were compared between the two groups rate. Results The rate of R0 resection in the NAC group was significantly higher than that in the CC group (P <0.05). The recurrence rate in the NAC group was lower than that in the CC group at 12 and 24 months (P <0.05) After 6, 12, 24 months lower than the CC group (P <0.05). Conclusions Neoadjuvant chemotherapy for stage Ⅲ gastric cancer is superior to conventional surgery plus postoperative chemotherapy in improving the R0 resection rate and reducing the postoperative recurrence rate and mortality of gastric cancer patients.